Lv3
368 积分 2024-12-18 加入
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
1个月前
已完结
Immune checkpoint therapy in locally advanced, persistent, recurrent, and metastatic cervical cancer: A systematic review and Bayesian network meta‐analysis
3个月前
已完结
A Phase II, Safety, and Efficacy Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Patients With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer
3个月前
已关闭
An Open-label, Phase 2 Randomized Trial of Camrelizumab (SHR1210) Plus Apatinib Versus Paclitaxel and Cisplatin/Carboplatin Plus Bevacizumab as a First-line Therapy in Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
3个月前
已关闭
The System Usability Scale: Past, Present, and Future
6个月前
已完结
Risk of ocular adverse events with aromatase inhibitors
6个月前
已完结
Ocular Toxicities in Chimeric Antigen Receptor T-Cell Therapy: A Real-World Study Leveraging FAERS Database
6个月前
已完结
Post-Marketing Safety of Tazemetostat in Antitumor Therapy: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System
8个月前
已完结
Comparison of Al18F-NOTA-FAPI-74 and 18F-FDG PET/CT in the Evaluation and Staging of Hepatobiliary Malignancies
8个月前
已完结
[Chinese experts consensus on the diagnosis and management of checkpoint inhibitor pneumonitis(2025)]
10个月前
已完结
皖公网安备34019202002308
